(Q37249965)

19 August 2017

A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer (English)

1 reference

19 August 2017

phase II clinical trial

0 references

1 reference

10

Gabriel N Hortobagyi

1 reference

19 August 2017

7

Aman U Buzdar

1 reference

19 August 2017

Stacy L Moulder

1

1 reference

19 August 2017

Frankie A Holmes

2

1 reference

19 August 2017

Anthony W Tolcher

3

1 reference

19 August 2017

Peter Thall

4

1 reference

19 August 2017

Kristine Broglio

5

1 reference

19 August 2017

Vicente Valero

6

1 reference

19 August 2017

Susan G Arbuck

8

1 reference

19 August 2017

Andrew Seidman

9

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 February 2010

1 reference

19 August 2017

1 reference

19 August 2017

116

1 reference

19 August 2017

4

1 reference

19 August 2017

814-821

1 reference

Evaluation of survival data and two new rank order statistics arising in its consideration

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806193

Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806193

Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806193

Long-term, weekly one-hour infusion of paclitaxel in patients with metastatic breast cancer: a phase II monoinstitutional study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806193

Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806193

Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01).

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806193

Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806193

Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806193

Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806193

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806193

Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26

3 December 2018

1 reference

12 December 2020

Weekly paclitaxel in metastatic breast cancer patients: a phase II study

1 reference

12 December 2020

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer

1 reference

12 December 2020

Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer

1 reference

12 December 2020

Nonparametric Estimation from Incomplete Observations

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCNCR.24870

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/CNCR.24870

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

20052721

1 reference